Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Urshansky, Nataly
Mausner-Fainberg, Karin [2 ]
Auriel, Eitan [2 ]
Regev, Keren
Bornstein, Natan M. [2 ,3 ]
Karni, Arnon [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Neurol, Neuroimmunol Lab & Clin, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Neurol, Stroke Unit, IL-64239 Tel Aviv, Israel
关键词
Noggin; Multiple sclerosis; T cells; Neurogenesis; OLIGODENDROCYTE PRECURSOR CELLS; REGULATORY T-CELLS; SPINAL-CORD-INJURY; DENDRITIC CELLS; NEUROTROPHIC FACTOR; STEM/PROGENITOR CELLS; FUNCTIONAL RECOVERY; GLATIRAMER ACETATE; CNS REMYELINATION; BRAIN-LESIONS;
D O I
10.1016/j.jneuroim.2010.10.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) plaques are characterized by neurodegeneration, astrogliolis, the presence of immature oligodendrocytes and infiltrating immune cells. Recent studies revealed a putative role for noggin in both neurogenesis and oligodenrocytes development. In order to study the potential of peripheral immune cells to contribute to neurogenesis in MS, we studied the mRNA expression, protein secretion and regulation profile of noggin in peripheral blood mononuclear cells (PBMCs) of untreated patients with relapsing-remitting MS (RR-MS), interferon-beta (IFN-beta) treated RR-MS patients compared to matched healthy controls (HC). Basal levels of noggin mRNA expression, determined by quantitative real-time PCR were lower in untreated patients than in HC. No differences were found between untreated patients and IFN-beta treated patients. Similarly, the secreted levels of noggin, detected in 24 h PBMCs supernatants by ELISA, were decreased in untreated RR-MS patients than in HC. Again no significant differences were found between untreated patients and IFN-beta treated patients. Stimulation with anti-CD3/CD28 mAbs increased noggin mRNA expression in untreated patients but not in HC. However, noggin mRNA levels in untreated patients PBMCs stimulated with anti-CD3/CD28 did not reach noggin levels in unstimulated PBMCs of HC. Purification of monocytes (CD14+) and T cells (CD3+ cells) by magnet-activated cell separation has demonstrated that noggin mRNA is predominantly expressed in CD3+ cells in both HC and in RR-MS patients. This pattern also appeared in protein level of noggin, tested by Western blot. The incubation of the PBMCs with TNF-alpha increased the expression of noggin only in HC group. In conclusion, T cells possess the potential to participate in the induction of neurogeneration by the production of noggin. This potential seems to be defective in immune cells of RR-MS patients as there is reduced mRNA expression and protein secretion levels of noggin, insufficient stimulatory effect of CD3/CD28 stimulation and unresponsiveness to TNF-alpha in these patients PBMCs. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 50 条
  • [41] PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Somilo, O., V
    Kalbus, O., I
    Makarov, S. O.
    Sorokin, A. V.
    Shastun, N. P.
    WORLD OF MEDICINE AND BIOLOGY, 2023, 84 (02): : 147 - 152
  • [42] Executive functions in relapsing-remitting multiple sclerosis
    Elosua, M. Rosa
    Villadangos, Noelia
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,
  • [43] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    Buscarinu, M. C.
    Romano, S.
    Mechelli, R.
    Umeton, R. Pizzolato
    Ferraldeschi, M.
    Fornasiero, A.
    Renie, R.
    Cerasoli, B.
    Morena, E.
    Romano, C.
    Loizzo, N. D.
    Umeton, R.
    Salvetti, M.
    Ristori, G.
    NEUROTHERAPEUTICS, 2018, 15 (01) : 68 - 74
  • [44] Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation
    Golan, Maya
    Krivitsky, Avivit
    Mausner-Fainberg, Karin
    Benhamou, Moshe
    Vigiser, Ifat
    Regev, Keren
    Kolb, Hadar
    Karni, Arnon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 17
  • [45] Therapeutic inertia in relapsing-remitting multiple sclerosis
    Rodrigues, Rita
    Rocha, Raquel
    Bonifacio, Goncalo
    Ferro, Daniela
    Sabenca, Francisco
    Goncalves, Ana Isabel
    Correia, Filipe
    Pinheiro, Joaquim
    Loureiro, Jose Leal
    Guerreiro, Rui Pedro
    Vale, Jose
    Sa, Maria Jose
    Costa, Andreia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
  • [46] Development of laquinimod for relapsing-remitting multiple sclerosis
    Jeffery, Douglas R.
    FUTURE NEUROLOGY, 2008, 3 (06) : 641 - 648
  • [47] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [48] Cognitive Impairment In Relapsing-Remitting Multiple Sclerosis
    Topcular, Baris
    Ozcan, M. Emin
    Kurt, Elif
    Kuscu, Demet Yandim
    Icen, Nilufer Kale
    Sutlas, Pakize Nevin
    Kirbas, Dursun
    Bingol, Ayhan
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (03): : 178 - 182
  • [49] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [50] Postural Control in Relapsing-Remitting Multiple Sclerosis
    Cusin, Flavia Salvaterra
    Tomaz, Andreza
    Gananca, Mauricio Malavasi
    Oliveira, Enedina Maria
    Falcao Goncalves, Alessandra Billi
    Caovilla, Heloisa Helena
    INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2022, 26 (04) : 592 - 604